Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...
The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
The researchers noted that their findings highlight the need to understand the challenges in delivering evidence-based care for chronic obstructive pulmonary disease (COPD). Patients who live in rural ...
Another study [3] was conducted by AstraZeneca at the request of the FDA to assess the safety of inhaled LABA drugs when added to inhaled glucocorticoid. Participants in this study were 12 years of ...
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
Results showed budesonide/glycopyrronium/formoterol fumarate 320/28.8/9.6μg met all primary endpoints in both KALOS and LOGOS. Topline data were announced from two ...
There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results